Cytodyn certainly has received some favorable press lately with bits and pieces of good news on results and third party endorsements. The one I find interesting is Citigroup placing a positive rating on it. Normally, they wouldn't bother with a low priced stock but for some reason they did. I can only surmise that they have an investment banking client (perhaps a global name) showing some interest. I believe Merck has used them in the past and with the safety profile of their HIV drug basically bombing, you know for sure they are sniffing around. It's not unusual for a firm to due some due diligence on something they either partner with or acquire, and Citigroup could do that.
Now before we go off to the races, more studies and research has to Be done but from this author's standpoint, things are beginning to look a whole lot better. Please vote!